www.nextgensciences.com
For release 13th November 2006 Jake Orville appointed as Vice-President of Global Sales to drive the commercialisation of NextGen’s products NextGen Group PLC, the AIM listed “gene to protein” company has appointed Jake Orville as Vice-President Global Sales to drive the commercialisation of the company’s products in North America, Europe and the Far East. His appointment comes just as the company has announced the acquisition of Proteomic Research Services Inc (PRS) of Michigan, USA. Jake’s appointment complements the appointment of Gareth Thomson to head up the company’s global marketing activities which was announced earlier this year. This appointment is a further sign of the company’s commitment to strengthening its commercial presence around the world as it develops new products in response to market needs and seeks to establish its contractexpress™ fee for service offering as an industry standard. Jake joins NextGen from Third Wave Technologies (Nasdaq: TWTI) where he was Vice-President of Sales and Business Development and led growth of clinical diagnostic revenues over a three-year period from less than $3.0 Million to $18.0 Million, with run rates exceeding $25 Million. Prior to that he worked for the SMITHS Group (LSE: SMIN.L) where he was Product Specialist of the Year in 1999 and after this, became their National Sales Manager until 2002. Orville will replace Dr Geoff Alms, who has taken on leadership of the N. American Business Development function. Commenting on Jake’s appointment Dr James G Heffernan, CEO said “We are extremely fortunate to attract someone as talented as Jake to lead our sales effort on a global basis. His track record of building sales teams capable of returning fast growth is amongst the strongest I have seen in this industry. He is a determined and focused individual who brings added strength in depth to our senior management team. In addition, we have recently identified a significant emerging application within the proteomics market which will require a great deal of technical expertise and commercial acumen to develop to its fullest potential. Geoff’s skill set is ideally suited to this role and I am delighted he has taken on the challenge. When coupled to the benefits that will accrue from the acquisition and total integration of PRS I believe we are setting the scene for a significant improvement in the sales performance of the company” “I am very pleased to be joining NextGen at this very exciting time in their evolution” said Mr. Orville. “They have an enviable portfolio of products developed to satisfy client needs and with the new fee for service offering, contractexpress™, to commercialise, I am looking forward to driving NextGen to a leadership position within the emerging Proteomics market.” Contacts: Dr James Heffernan, CEO 01480 420 979 NextGen Group PLC Mike Wort, Anna Dunphy 0207 744 7711 MC Bio-Communications Notes to Editors: About NextGen Sciences NextGen Group PLC (LSE:NGG) is a provider of expert systems, services and reagents focused on enabling enhanced access to and understanding of the role of proteins in diagnosis and drug discovery. The expert systems are built out of NextGen’s understanding of biological sciences and combine robotics, advanced engineering and rules based software in systems that range from partial to fully automated. NextGen also uses its systems and instruments, and those of recently acquired PRS Inc. to provide fee-for-service products under the Brand Name contractexpress™ to the pharmaceutical and biotechnology industry as well as those in academic research. NextGen Group PLC floated on the AIM market in London in December 2005 raising £2.4 million in an oversubscribed offering which included strong institutional investor support from Germany as well as in the UK. Further details relating to NextGen Group PLC and its products can be found at www.nextgensciences.com
If you can’t open this electronic message, visit www.nextgensciences.com
about us>
© NextGen Sciences Ltd 2006, All rights reserved If this information is not of interest to you, and you no longer wish to receive press releases, we apologise for any inconvenience caused. To be removed from further emails please click here